JP2022520747A5 - - Google Patents

Info

Publication number
JP2022520747A5
JP2022520747A5 JP2021545375A JP2021545375A JP2022520747A5 JP 2022520747 A5 JP2022520747 A5 JP 2022520747A5 JP 2021545375 A JP2021545375 A JP 2021545375A JP 2021545375 A JP2021545375 A JP 2021545375A JP 2022520747 A5 JP2022520747 A5 JP 2022520747A5
Authority
JP
Japan
Prior art keywords
tmt
compound
pharmaceutical composition
optionally substituted
ataxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520747A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016441 external-priority patent/WO2020163245A1/en
Publication of JP2022520747A publication Critical patent/JP2022520747A/ja
Publication of JP2022520747A5 publication Critical patent/JP2022520747A5/ja
Priority to JP2025018867A priority Critical patent/JP2025072556A/ja
Pending legal-status Critical Current

Links

JP2021545375A 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法 Pending JP2022520747A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018867A JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US62/800,996 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US62/851,433 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US62/894,167 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US62/937,618 2019-11-19
US202062962647P 2020-01-17 2020-01-17
US62/962,647 2020-01-17
PCT/US2020/016441 WO2020163245A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018867A Division JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Publications (2)

Publication Number Publication Date
JP2022520747A JP2022520747A (ja) 2022-04-01
JP2022520747A5 true JP2022520747A5 (https=) 2023-02-10

Family

ID=69743942

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021545375A Pending JP2022520747A (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2021545383A Active JP7511567B2 (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2025018867A Pending JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021545383A Active JP7511567B2 (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2025018867A Pending JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Country Status (13)

Country Link
US (2) US20220016092A1 (https=)
EP (2) EP3920913A1 (https=)
JP (3) JP2022520747A (https=)
KR (2) KR20210123353A (https=)
CN (2) CN113645969A (https=)
AU (2) AU2020217659B2 (https=)
BR (2) BR112021015172A2 (https=)
CA (1) CA3128039A1 (https=)
IL (3) IL285304B2 (https=)
MX (2) MX2021009384A (https=)
SG (2) SG11202107842QA (https=)
TW (3) TW202045168A (https=)
WO (2) WO2020163245A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Similar Documents

Publication Publication Date Title
JP2022520747A5 (https=)
TWI511728B (zh) 包含非典型抗精神病藥物及taar1激動劑之醫藥組合
JP2022519131A5 (https=)
RU2378259C2 (ru) Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции
CA2153340C (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
CN112898196B (zh) 有效的可溶性环氧化物水解酶抑制剂
KR102051485B1 (ko) Bace 매개 app 처리과정을 조절하는 히단토인
US20250019351A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
FR2847253A1 (fr) Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US12084451B2 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
CN112638866B (zh) 索拉非尼衍生物的共晶体及其制备方法
US12258308B2 (en) Benzene derivative
US20210238192A1 (en) Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
ES3057235T3 (en) Isoxazolidines as ripk1 inhibitors and use thereof
US9284325B2 (en) Spectinamides as anti-tuberculosis agents
JP2022519274A5 (https=)
JPWO2006137465A1 (ja) 含窒素複素環誘導体
US20120302607A1 (en) C4-substituted alpha-keto oxazoles
WO2003040142A1 (fr) Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
JP2023535483A5 (https=)
EP1349850B1 (fr) Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
WO2020219935A1 (en) Dual inhibitors of soluble epoxide hydrolase and methods of use thereof
JP2022502441A5 (https=)
WO2025228562A1 (en) Carbazole derivatives used as neuroprotectants and in the treatment of disorders with reduced nad metabolism